Skip to main content
SpringerLink
Log in

Direct inhibition of neutral endopeptidase in vasopeptidase inhibitor-mediated amelioration of cardiac remodeling in rats with chronic heart failure

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Vasopeptidase inhibitors possess dual inhibitory actions on neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE) and have beneficial effects on cardiac remodeling. However, the contribution of NEP inhibition to their effects is not yet fully understood. To address the role of cardiac NEP inhibition in the anti-remodeling effects of a vasopeptidase inhibitor, we examined the effects of omapatrilat on the development of cardiac remodeling in rats with left coronary artery ligation (CAL) and those on collagen synthesis in cultured fibroblast cells. In vivo treatment with omapatrilat (30 mg/kg/day for 5 weeks) inhibited cardiac NEP activity in rats with CAL, which was associated with a suppression of both cardiac hypertrophy and collagen deposition. In cultured cardiac fibroblasts, omapatrilat (10−7~10−5 M) inhibited NEP activity and augmented the ANP-induced decrease in [3H]-proline incorporation. ONO-BB, an active metabolite of the NEP selective inhibitor ONO-9902, also augmented the ANP-induced response, whereas captopril, an ACE inhibitor, did not. The angiotensin I-induced increase in [3H]-proline incorporation was prevented by omapatrilat and captopril, but not by ONO-BB. The results suggest that vasopeptidase inhibitor suppressed cardiac remodeling in the setting of chronic heart failure, possibly acting through the direct inhibition of cardiac NEP. Vasopeptidase inhibitors may have therapeutic advantages over the classical ACE and NEP inhibitors alone with respect to the regression of cardiac fibrosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schaper J, Speiser B: The extracellular matrix in the failing human heart. Basic Res Cardiol 87: 303-309, 1992

    Google Scholar 

  2. Sabbah HN, Sharov VG, Lesch M, Goldstein S: Progression of heart failure: A role for interstitial fibrosis. Mol Cell Biochem 147: 29-34, 1995

    Google Scholar 

  3. Pelouch V, Dixon IM, Golfman L, Beamish RE, Dhalla NS: Role of extracellular matrix proteins in heart function. Mol Cell Biochem. 129: 101-120, 1993

    Google Scholar 

  4. Dixon IM, Ju H, Jassal DS, Peterson DJ: Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarction. Mol Cell Biochem 165: 31-45, 1996

    Google Scholar 

  5. Nwogu JI, Geenen D, Bean M, Brenner MC, Huang X, Buttrick PM: Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation 104: 2216-2221, 2001

    Google Scholar 

  6. Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T: Contribution of cardiac renin-angiotensin system to ventricular remodeling in myocardial-infarcted rats. J Mol Cell Cardiol 25: 1369-1380, 1993

    Google Scholar 

  7. Sakai S, Miyauchi T, Sakurai T, Kasuya Y, Ihara M, Yamaguchi I, Goto K, Sugishita Y: Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure: Marked increase in endothelin-1 production in the failing heart. Circulation 93: 1214-1222, 1996

    Google Scholar 

  8. Bralet J, Schwartz JC: Vasopeptidase inhibitors: An emerging class of cardiovascular drugs. Trends Pharmacol Sci 22: 106-109, 2001

    Google Scholar 

  9. Corti R, Burnett JC Jr, Rouleau JL, Ruschitzka F, Luscher TF: Vasopeptidase inhibitors: A new therapeutic concept in cardiovascular disease? Circulation 104: 1856-1862, 2001

    Google Scholar 

  10. Trippodo NC, Fox M, Monticello TM, Panchal BC, Asaad MM: Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol 34: 782-790, 1999

    Google Scholar 

  11. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ: Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 356: 615-620, 2000

    Google Scholar 

  12. Packer M, Califf RM, Konstam MA, Krum H, Mcmurray JJ, Rouleau JL, Swedberg K: Comparison of omapatrilat and enalapril in patients with chronic heart failure: The omapatrilat vs. enalapril randomized trial of utility in reducing events (OVERTURE). Circulation 106: 920-926, 2002

    Google Scholar 

  13. Lapointe N, Blais C Jr, Adam A, Parker T, Sirois MG, Gosselin H, Clement R, Rouleau JL: Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat. J Am Coll Cardiol 39: 1692-1698, 2002

    Google Scholar 

  14. Cleutjens JP, Verluyten MJ, Smiths JF, Daemen MJ: Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol 147: 325-338, 1995

    Google Scholar 

  15. Sun Y, Zhang JQ, Zhang J, Lamparter S: Cardiac remodeling by fibrous tissue after infarction in rats. J Lab Clin Med 135: 316-323, 2000

    Google Scholar 

  16. Sanbe A, Tanonaka K, Hanaoka Y, Katoh T, Takeo S: Regional energy metabolism of failing hearts following myocardial infarction. J Mol Cell Cardiol 25: 995-1013, 1993

    Google Scholar 

  17. Intengan HD, Schiffrin EL: Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats. Hypertension 35: 1221-1225, 2000

    Google Scholar 

  18. Maki T, Nasa Y, Yamaguchi F, Yoshida H, Mori M, Takada T, Horikawa E, Okano K, Takeo S: Long-term treatment with neutral endopeptidase inhibitor improves cardiac function and reduces natriuretic peptides in rats with chronic heart failure. Cardiovasc Res 51: 608-617, 2001

    Google Scholar 

  19. Tsai BS, Peach MJ: Angiotensin homologs and analogs as inhibitors of rabbit pulmonary angiotensin-converting enzyme. J Biol Chem 252: 4674-4681, 1977

    Google Scholar 

  20. Yoshida H, Takahashi M, Tanonaka K, Maki T, Nasa Y, Takeo S: Effects of ACE inhibition and angiotensin II type 1 receptor blockade on cardiac function and G proteins in rats with chronic heart failure. Br J Pharmacol 134: 150-160, 2001

    Google Scholar 

  21. Maki T, Horio T, Yoshihara F, Suga S, Takeo S, Matsuo H, Kangawa K: Effect of neutral endopeptidase inhibitor on endogenous atrial natriuretic peptide as a paracrine factor in cultured cardiac fibroblasts. Br J Pharmacol 131: 1204-1210, 2000

    Google Scholar 

  22. Burrell LM, Droogh J, Man in't Veld O, Rockell MD, Farina NK, Johnston CI: Antihypertensive and antihypertrophic effects of omapatrilat in SHR. Am J Hypertens 13: 1110-1116, 2000

    Google Scholar 

  23. Pu Q, Touyz RM, Schiffrin EL: Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 20: 899-907, 2002

    Google Scholar 

  24. Weber MA: Vasopeptidase inhibitors. Lancet 358: 1525-1532, 2001

    Google Scholar 

  25. Schoemaker RG, Debets JJ, Struyker-Boudier HA, Smits JF: Delayed but not immediate captopril therapy improves cardiac function in conscious rats, following myocardial infarction. J Mol Cell Cardiol 23: 187-197, 1991

    Google Scholar 

  26. Weber KT: Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation. Circulation 96: 4065-4082, 1997

    Google Scholar 

  27. Sun Y, Cleutjens JP, Diaz-Arias AA, Weber KT: Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat. Cardiovasc Res 28: 1423-1432, 1994

    Google Scholar 

  28. Weber KT, Sun Y, Katwa LC: Myofibroblasts and local angiotensin II in rat cardiac tissue repair. Int J Biochem Cell Biol 29: 31-42, 1997

    Google Scholar 

  29. Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H: Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension 25: 1252-1259, 1995

    Google Scholar 

  30. Linz W, Wiemer G, Schaper J, Zimmermann R, Nagasawa K, Gohlke P, Unger T, Scholkens BA: Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis. Mol Cell Biochem 147: 89-97, 1995

    Google Scholar 

  31. Monopoli A, Ongini E, Cigola E, Olivetti G: The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. J Cardiovasc Pharmacol 20: 496-504, 1992

    Google Scholar 

  32. Pu Q, Schiffrin EL: Effect of ACE/NEP inhibition on cardiac and vascular collagen in stroke-prone spontaneously hypertensive rats. Am J Hypertens 14: 1067-1072, 2001

    Google Scholar 

  33. Piedimonte G, Nadel JA, Long CS, Hoffman JI: Neutral endopeptidase in the heart neutral endopeptidase inhibition prevents isoproterenol-induced myocardial hypoperfusion in rats by reducing bradykinin degradation. Circ Res 75: 770-779, 1994

    Google Scholar 

  34. Fielitz J, Dendorfer A, Pregla R, Ehler E, Zurbrugg HR, Bartunek J, Hetzer R, Regitz-Zagrosek V: Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure. Circulation 105: 286-289, 2002

    Google Scholar 

  35. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, Pandey KN, Milgram SL, Smithies O, Maeda N: Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci USA 94: 14730-14735, 1997

    Google Scholar 

  36. Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T, Takahashi N, Kawakami R, Tanimoto K, Nakagawa Y, Nakanishi M, Adachi Y, Garbers DL, Fukamizu A, Nakao K: Guanylyl cyclase-A inhibits angiotensin II type 1 A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart. Circulation 106: 1722-1728, 2002

    Google Scholar 

  37. Harada K, Sugaya T, Murakami K, Yazaki Y, Komuro I: Angiotensin II type 1 A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 100: 2093-2099, 1999

    Google Scholar 

  38. Chen HH, Lainchbury JG, Matsuda Y, Harty GJ, Burnett JC Jr: Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure. Hypertension 38: 187-191, 2001

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, Tokyo University of Pharmacy and Life Science, 14321-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan

    Toshiyuki Maki, Yoshihisa Nasa, Kouichi Tanonaka, Masaya Takahashi & Satoshi Takeo

Authors
  1. Toshiyuki Maki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshihisa Nasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kouichi Tanonaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masaya Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Satoshi Takeo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maki, T., Nasa, Y., Tanonaka, K. et al. Direct inhibition of neutral endopeptidase in vasopeptidase inhibitor-mediated amelioration of cardiac remodeling in rats with chronic heart failure. Mol Cell Biochem 254, 265–273 (2003). https://doi.org/10.1023/A:1027337601863

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1027337601863

Search

Navigation